LINC01432binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapy

Abstract

AbstractMultiple Myeloma (MM) is a highly prevalent and incurable form of cancer that arises from malignant plasma cells, with over 35,000 new cases diagnosed annually in the United States. While there are a growing number of approved therapies, MM remains incurable and nearly all patients will relapse and exhaust all available treatment options. Mechanisms for disease progression are unclear and in particular, little is known regarding the role of long non-coding RNAs (lncRNA) in mediating disease progression and response to treatment. In this study, we used transcriptome sequencing to compare newly diagnosed MM patients who had short progression- free survival (PFS) to standard first-line treatment (PFS < 24 months) to patients who had prolonged PFS (PFS > 24 months). We identified 157 differentially upregulated lncRNAs with short PFS and focused our efforts on characterizing the most upregulated lncRNA,LINC01432. We investigatedLINC01432overexpression and CRISPR/Cas9 knockdown in MM cell lines to show thatLINC01432overexpression significantly increases cell viability and reduces apoptosis, while knockdown significantly reduces viability and increases apoptosis, supporting the clinical relevance of this lncRNA. Next, we used individual-nucleotide resolution cross-linking immunoprecipitation with RT-qPCR to show thatLINC01432directly interacts with the RNA binding protein, CELF2. Lastly, we showed thatLINC01432-targeted locked nucleic acid antisense oligonucleotides reduce viability and increases apoptosis. In summary, this fundamental study identified lncRNAs associated with short PFS to standard NDMM treatment and further characterizedLINC01432,which inhibits apoptosis.Key points:lncRNA expression was found to be dysregulated in patients with short PFS to standard multiple myeloma therapy.LINC01432-bound CELF2 inhibits apoptosis.